Robert F. Carey
About Robert F. Carey
Robert F. Carey is a Director with extensive experience in the biotech and pharmaceutical industries, having held leadership positions at companies such as ACELYRIN, INC., Horizon, and currently at Beyond Air™ and Sangamo Therapeutics, Inc. He has expertise in private placements, public offerings, and licensing, supported by a background in accounting from the University of Notre Dame.
Current Role at Sangamo Therapeutics
Robert F. Carey has been serving as a Director at Sangamo Therapeutics, Inc. since 2016. His role involves strategic oversight and guidance in the development of innovative therapies within the biotech sector. Sangamo Therapeutics focuses on genomic medicine, and Carey's expertise contributes to the company's mission of advancing transformative therapies.
Previous Experience at ACELYRIN, INC.
Carey held the position of President at ACELYRIN, INC. from 2020 to 2022. During his tenure, he was responsible for leading the company's strategic initiatives and operations in Woodland Hills, California. His leadership played a role in the company's focus on developing and commercializing innovative therapies in the biotech field.
Background in Financial Services
Prior to his roles in the biotech industry, Carey worked at Dresdner Kleinwort Wasserstein as Managing Director for one year, from 2001 to 2002. He also served as Executive Vice President and Chief Business Officer at Horizon from 2014 to 2019. His experience in financial services includes expertise in private placements and PIPE transactions, which are crucial for funding in the biotech and pharmaceutical sectors.
Education and Expertise
Robert F. Carey studied at the University of Notre Dame, where he earned a Bachelor of Business Administration in Accounting from 1976 to 1981. His educational background laid the foundation for his extensive experience in public offerings and licensing within the biotech and pharmaceutical industries. He also attended Fenwick High School from 1972 to 1976.
Specialized Skills in Biotech Transactions
Carey possesses significant expertise in licensing and public offerings, which are essential for navigating the complexities of the biotech and pharmaceutical markets. His skills in negotiating and securing rights to intellectual property, along with his understanding of taking companies public, enhance his contributions to the organizations he has been part of.